Solaxa, Inc.
Solaxa is a clinical-stage biopharmaceutical company dedicated to developing treatments for rare neurodegenerative diseases and nerve injuries. They focus on restoring nerve function by targeting ion channels, with a mission to improve patient outcomes through impactful and accessible therapies. The company is organized as a public benefit corporation, emphasizing societal health alongside profitability.
Industries
Nr. of Employees
small (1-50)
Solaxa, Inc.
Products
Investigational reformulated aminopyridine therapy for spinocerebellar ataxia (registrational candidate)
A reformulated aminopyridine-class small molecule developed to address ion channel dysfunction in spinocerebellar ataxia; advanced to IND-cleared clinical studies and planned for registrational Phase 3 evaluation.
Pharmacologic diagnostic application for peripheral nerve injury assessment
Clinical application under study using an ion channel–blocking small molecule to transiently restore function in non-severed peripheral nerves, enabling early differentiation between severed and recoverable injuries.
Investigational reformulated aminopyridine therapy for spinocerebellar ataxia (registrational candidate)
A reformulated aminopyridine-class small molecule developed to address ion channel dysfunction in spinocerebellar ataxia; advanced to IND-cleared clinical studies and planned for registrational Phase 3 evaluation.
Pharmacologic diagnostic application for peripheral nerve injury assessment
Clinical application under study using an ion channel–blocking small molecule to transiently restore function in non-severed peripheral nerves, enabling early differentiation between severed and recoverable injuries.
Services
Regulatory sponsorship and clinical trial coordination
Acting as regulatory sponsor for human studies, coordinating trial setup with clinical sites and centers of expertise for registrational studies.
Sponsored research agreements and natural history study support
Funding and management of sponsored research agreements with disease foundations to expand natural history cohorts and support diagnostic/genetic testing programs.
Preclinical and clinical drug development for ion channel therapeutics
Development activities encompassing reformulation and clinical evaluation of ion channel–targeting small molecules for neurological indications.
Grant and non-dilutive funding facilitation
Securing and managing non-dilutive grants and public investments to support research and development activities.
Regulatory sponsorship and clinical trial coordination
Acting as regulatory sponsor for human studies, coordinating trial setup with clinical sites and centers of expertise for registrational studies.
Sponsored research agreements and natural history study support
Funding and management of sponsored research agreements with disease foundations to expand natural history cohorts and support diagnostic/genetic testing programs.
Preclinical and clinical drug development for ion channel therapeutics
Development activities encompassing reformulation and clinical evaluation of ion channel–targeting small molecules for neurological indications.
Grant and non-dilutive funding facilitation
Securing and managing non-dilutive grants and public investments to support research and development activities.
Expertise Areas
- Clinical trial management
- Regulatory strategy and submissions (IND, orphan designation)
- Rare disease drug development
- Neuropharmacology and ion channel therapeutics
Key Technologies
- Small-molecule ion channel modulators
- Aminopyridine-class therapeutics
- Drug repurposing methodologies
- Registrational clinical trial design